RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Kineret
Synonyms :
anakinra
Class :
Disease Modifying Antirheumatic Drugs, Immunomodulators
Brand Name :
Kineret
Synonyms :
anakinra
Class :
Disease Modifying Antirheumatic Drugs, Immunomodulators
Dosage Forms & Strengths
Prefilled syringes
100mg/0.67ml
Administer dose of 100 mg subcutaneously daily
Cryopyrin Associated Periodic Syndromes
Administer an initial dose of 1 to 2 mg/kg subcutaneously daily
Then it may raise up to 0.5 to 1 mg/kg
Dose should not be more than 8 mg/kg
As Emergency use authorization
Administer dose of 100 mg subcutaneously daily for 10 days
Dosage Modifications
Renal Impairment
For Mild-to-moderate: Mean plasma clearance was decreased by 16 to 50%
Hepatic impairment
Study not carried out
Dosing Considerations
Measure white blood cells before starting, then every month up to 3 months and then quarterly up to one year
Dosage Forms & Strengths
Prefilled syringes
100mg/0.67ml
Cryopyrin Associated Periodic Syndromes
Administer an initial dose of 1 to 2 mg/kg subcutaneously daily
Then it may raise up to 0.5 to 1 mg/kg
Dose should not be more than 8 mg/kg
Dosing Considerations
Measure white blood cells before starting, then every month up to 3 months and then quarterly up to one year
Refer to adult dosing
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of other antirheumatic drugs
may increase the immunosuppressive effect of other antirheumatic drugs
may increase the immunosuppressive effect of other antirheumatic drugs
may increase the immunosuppressive effect of other antirheumatic drugs
may increase the immunosuppressive effect of other antirheumatic drugs
When anakinra is used in combination with rabies vaccine, this leads to a reduction in the rabies vaccine effects through the process of pharmacodynamic antagonism
when anakinra is used in combination with diphtheria & tetanus toxoids, this leads to a reduction in the effects of diphtheria & tetanus toxoids through pharmacodynamic antagonism
interaction raises immunosuppressive effects and risk of infection
it may increase the risk of adverse effects of anakinra
may increase the immunosuppressive effect of other antirheumatic drugs
may increase the immunosuppressive effect of other antirheumatic drugs
may increase the immunosuppressive effect of other antirheumatic drugs
may increase the immunosuppressive effect of other antirheumatic drugs
may increase the immunosuppressive effect of other antirheumatic drugs
pneumococcal vaccine polyvalent
the activity of pneumococcal vaccine polyvalent is reduced due to pharmacodynamic antagonism
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of anakinra
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of anakinra
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of anakinra
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of anakinra
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of anakinra
Combining levobetaxolol and anakinra can enhance levobetaxolol’s metabolism
Combining tegafur with anakinra can reduce tegafur’s metabolism
It may enhance the risk of adverse effects when combined with Interleukins
It may enhance the risk of adverse effects when combined with Interleukins
It may enhance the risk of adverse effects when combined with Interleukins
It may enhance the risk of adverse effects when combined with Interleukins
It may enhance the risk of adverse effects when combined with Interleukins
When acetohexamide is used together with anakinra, this lead to rise in acetohexamide’s metabolism
When mometasone furoate is used together with anakinra, this leads to enhanced risk or seriousness of adverse outcomes
poliovirus vaccine inactivated
the poliovirus vaccine's inactivation caused by pharmacodynamic antagonist is lessened by anakinra
anakinra: it may increase the metabolism of oxtriphylline
anakinra: it may decreased the serum concentration of CNS depressants
anakinra: it may decreased the serum concentration of CNS depressants
anakinra: it may decreased the serum concentration of CNS depressants
anakinra: it may decreased the serum concentration of CNS depressants
anakinra: it may decreased the serum concentration of CNS depressants
the metabolism of dapoxetine may be increased when combined with anakinra
when both drugs are combined, there may be an increased metabolism of etoposide
when both drugs are combined, there may be a high metabolism of paclitaxel
when both the drugs are combined, the metabolism of carmustine increases
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk of serious infections
both, if used simultaneously, show immunosuppression risk of infection increases on administering both the drugs simultaneously
When both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections
the efficacy of the vaccine may be reduced
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the rate of metabolism of methoxyflurane may be increased
When anakinra is used together with lomitapide, this leads to an enhancement in lomitapide’s metabolism
the activity of the anthrax vaccine can be reduced when used in combination with anakinra
Actions and Spectrum
anakinra inhibits the activity of interlukin-1 (IL-1) by competitively binding to the IL-1 receptor. This prevents IL-1 from exerting its pro-inflammatory effects on cells and tissues. anakinra helps to reduce inflammation and alleviate symptoms associated with various inflammatory conditions.
Frequency defined
>10%
Injection-site reaction
Headache
Nasopharyngitis
Transaminases increased
Vomiting
Arthralgia
Headache
Injection site reaction
Pyrexia
GGT increased
1-10%
Leukopenia
Neutropenia
Hyperkalemia
Anxiety
Hypothermia
Acute kidney injury
Nausea
Diarrhea
Hypernatremia
Rash
<1%
Neutropenia
Post marketing Reports
Hepatobiliary disorders
Thrombocytopenia
Severe thrombocytopenia
Elevated transaminases
Noninfectious hepatitis
Black Box Warning
None
Contraindication/Caution:
Contraindication:
Caution:
Pregnancy consideration:
Pregnancy category: N/A
Lactation: Excretion into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
anakinra helps reduce the inflammatory response. IL-1 is a potent pro-inflammatory cytokine which is important in the body’s immune response, and its excessive activation is associated with various inflammatory and autoimmune diseases.
It also modulates immune responses by inhibiting IL-1-mediated signals. This can be beneficial in autoimmune diseases and other conditions characterized by an overactive immune system.
Pharmacodynamics
anakinra is a recombinant form of the human interleukin-1 receptor antagonist (IL-1Ra). It binds to the IL-1 receptor (IL-1R), therefore blocking the binding of IL-1α and IL-1β to the receptor.
Pharmacokinetics
Absorption
anakinra is absorbed slowly and peak plasma concentrations is achieved within 3 to 7 hours through subcutaneous injection.
Distribution
anakinra is distributed throughout the body.
Metabolism
anakinra is not extensively metabolized in the body.
Elimination and excretion
anakinra is excreted via the kidneys. It has a short half-life, approximately 4 to 6 hours.
Administration
anakinra is typically administered as a subcutaneous injection.
Patient information leaflet
Generic Name: anakinra
Why do we use anakinra?
anakinra is used for the treatment of moderate to severe rheumatoid arthritis.
anakinra is used in the management of Cryopyrin-Associated Periodic Syndromes (CAPS).
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
